LIDDAMENT, Mark Terence,DOYLE, Anthony,CLARKE, Adam,LAINE, David Jose Simon,COOKSEY, Bridget Ann
申请号：
PE2019001295
公开号：
PE20191662A1
申请日:
2017.12.20
申请国别(地区):
PE
年份:
2019
代理人:
摘要：
It refers to a human antibody, which is organically combined with IL-5 in immunity, including: a heavy chain chlorinated paraffin, including SEQ ID No.4 sequence； a heavy chain chlorinated paraffin, including SEQ ID No.6 sequence； a heavy chain chlorinated paraffin, including SEQ ID No.8 sequence； a light chain chlorinated paraffin, including SEQ ID 5, 21, 24, 27, 30, 33, 36, 39 or 66, including SCCPs with SEQ ID 7, 42 or 45, and SCCPs with SEC 15, 48, 51, 54, 57, 60 or 63. In addition, the antibody includes: (a) a s28p mutation； (b) a m252y mutation,T256e variant s2554t and t256e mutations； or (c) residual inhibition from the lysine C-heavy chain terminal； or (d) any combination of a and C. this antibody is characterized by a reduction in the combination of IL-5 to the recipient of IL-5 and a continuous life expectancy of at least 20 days； it is effective in the treatment of EOC asthma, High blood pressure, sindrome, like everyone else He also mentioned a nucleic acid molecule, a vector, an antibody encoded by a skeletal cell and a pharmacological synthesis, including this antibody.Referido a un anticuerpo humano, el cual se une inmunoespecificamente a IL-5 humana, que comprende: una CDR1 de cadena pesada que comprende la secuencia de SEQ ID NO: 4； una CDR2 de cadena pesada que comprende la secuencia de SEQ ID NO: 6； una CDR3 de cadena pesada que comprende la secuencia de SEQ ID NO: 8； una CDR1 de cadena ligera que comprende la secuencia de SEQ ID NOs: 5, 21, 24, 27, 30, 33, 36, 39 o 66, una CDR2 de cadena ligera que comprende la secuencia de SEQ ID NOs: 7, 42 o 45, y una CDR3 de cadena ligera que comprende la secuencia de SEC ID NOs: 15, 48, 51, 54, 57, 60 o 63. Ademas, dicho anticuerpo comprende: a) una mutacion S228P； b) una mutacion M252Y, una mutacion S254T y una mutacion T256E； c) una supresion de residuo de lisina C-terminal de cadena pesada； o d) cualquier combinacion de a hasta c. Dicho anticuerpo se caracteriza por reducir la union de IL-5 al receptor de
